Use of B.C.G. as loco-regional aspecific immunostimulator in cervical carcinoma.
This study concerns the possible use of BCG in oncologic gynecology for loco regionauthorsl stimulation or loco aspecific active immunotherapy. The authors administered BCG into the portio of 45 women affected by cervical cancer (stage I and stage II) immediately after the cytohistologic diagnosis and 21 days before the surgical intervention. The authors conclude that the submucosal inoculation of BCG into the portio causes hyperplastic reactions in this area and in the loco-regional lymphatic system with stimulation of the T-lymphocytes and with production of Interferon. Anyway this stimulation has a limited duration.
D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine